Infinity Announces Clinical And Preclincal Data For Duvelisib To Be Presented at ASH 2014 Annual Meeting

Infinity Pharmaceuticals, Inc.

today announced that new data for duvelisib (IPI-145), an oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, will be presented at the American Society of Hematology (ASH) 2014 Annual Meeting, which is being held December 6-9 in San Francisco, CA. Key results to be presented during the meeting include translational data showing the complementary effects of inhibiting both PI3K-delta and PI3K-gamma as well as updated data from the Phase 1 study evaluating the safety and activity of duvelisib in patients with relapsed/refractory indolent non-Hodgkin lymphoma (iNHL) and relapsed/refractory chronic lymphocytic leukemia (CLL). Updated Phase 1 data on the activity of duvelisib in patients with T-cell lymphoma will also be reported. Presentations of duvelisib at ASH 2014 include the following: Sunday, December 7, 2014, 6:00 p.m. – 8:00 p.m. PT (poster presentation) Title: Duvelisib (IPI-145), a PI3K-δ,γ inhibitor, is clinically active in patients with relapsed/refractory chronic lymphocytic leukemia Abstract Number: 3334 Lead Author: Susan O'Brien, MD, Ashbel Smith Professor and Chief, Section of Acute Lymphocytic Leukemia in the Department of Leukemia, University of Texas, M.D. Anderson Cancer Center